Clinical trials: Young Adult Cancer
Diffuse Midline Glioma (DMG), Glioblastoma
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
This phase I trial studies the effects and best dose of ONC206 alone or in combination with radiation therapy in treating patients with diffuse midline gliomas that is newly diagnosed or has come back (recurrent) or other…
- Conditions
- Diffuse Midline Glioma (DMG), Glioblastoma, Recurrent Ependymoma, Recurrent Malignant Central Nervous System Neoplasm
- Trial name
- PNOC023 (NCT04732065)
- Testing
- ONC206, Standard of Care Radiation Therapy, Optional Proton (1H) MR spectroscopy (MRS)
- Where
- 7 sites in United States, Netherlands and 1 more
- Volunteers
- 208 people
- Sponsor
- Sabine Mueller, MD, PhD
Myeloproliferative Neoplasm
Children, Adolescents and Young Adults with Myeloproliferative Neoplasia: Study of Clinico-biological Characteristics and Complications (VYP)
The creation of a national database will provide access to solid data on the diagnosis of myeloproliferative neoplasia for patients under 30, giving a true picture of their care.
- Trial name
- VYP (NCT06715267)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Brest
Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
This is a research study to find out if adding a new study drug called revumenib to commonly used chemotherapy drugs is safe and if they have beneficial effects in treating patients with acute myeloid leukemia (AML) or acute…
- Conditions
- Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Leukemia of Ambiguous Lineage
- Trial name
- NCT06177067
- Testing
- Revumenib, Venetoclax, Azacitidine
- Where
- 10 sites in United States
- Volunteers
- 24 people
- Sponsor
- St. Jude Children's Research Hospital
Leukemia, Acute Lymphoblastic Leukemia
Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies
The primary purpose of this study is to determine safety, feasibility, and the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of CD22 Chimeric Antigen Receptor T-Cell Therapy (CART) cells when administered 28 to 42…
- Trial name
- NCT06408194
- Testing
- CD22CART infusion, Tisagenlecleucel
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Stanford University
COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm
The Effect of COVID-19 Pandemic on Adolescent and Young Adult Cancer Patients and Survivors
The study investigates how the COVID-19 pandemic has impacted the psychological, financial, physical, and social well-being of adolescent and young adult (AYA) cancer patients and survivors.
- Conditions
- COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT04551378
- Testing
- Quality-of-Life Assessment, Survey Administration
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- M.D. Anderson Cancer Center
Cigarette Smoking
A Randomized Controlled Trial to Test the Effect of a Smartphone Quit Smoking Intervention on Young Adult Smokers
The primary aim of this study will be to determine the effectiveness of a smartphone delivered app for young adult smokers on quitting smoking.
- Trial name
- NCT01983150
- Testing
- Crush the Crave Application, On the Road to Quitting - Self Help
- Where
- Canada
- Volunteers
- 1,601 people, healthy volunteers welcome
- Sponsor
- University of Waterloo
Cancer Survivor
Peer Mentoring in Promoting Follow-up Care Self-Management in Younger Childhood Cancer Survivors
This pilot trial studies a peer mentoring and online self-management program to see how well it works in promoting follow-up care self-management in younger childhood cancer survivors.
- Trial name
- NCT02699996
- Testing
- Questionnaire Administration, Telephone-Based Intervention
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Rutgers, The State University of New Jersey